Bluejay Therapeutics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Bluejay Therapeutics is a clinical-stage biopharmaceutical company developing therapies for chronic hepatitis B and liver diseases; raised over $100M; lead candidate BJT-778 entered clinical trials;
About
Bluejay Therapeutics is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Redwood City, California. The company is focused on developing innovative therapies for chronic liver diseases, with hepatitis B virus (HBV) infection as its primary indication. Chronic HBV is a significant unmet medical need affecting an estimated 296 million people worldwide; while existing antivirals like tenofovir and entecavir suppress the virus effectively, they do not achieve a functional cure and require lifelong treatment. Bluejay''s therapeutic programs aim to achieve functional cure — defined as durable suppression of HBV surface antigen (HBsAg) after treatment ends — by targeting viral replication mechanisms and immune restoration simultaneously.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.